Recursion Pharmaceuticals, Inc.
RXRX
Rank in Stocks
#5373
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in... Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Share Price
$3.81
Last synced: 2026-11-09
Market Cap
$2.37B
Change (1 day)
8.10%
Change (1 year)
-19.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Recursion Pharmaceuticals, Inc. (RXRX)
Category
Healthcare
EPS for Recursion Pharmaceuticals, Inc. (RXRX)
EPS as of September 2026 TTM: $-0.90
According to Recursion Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-0.90. At the end of 2025 the company had an EPS of $-1.44, an increase over its 2024 EPS of $-1.69.
EPS history for Recursion Pharmaceuticals, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.90 | -37.50% |
| 2025 | $-1.44 | -14.79% |
| 2024 | $-1.69 | 6.96% |
| 2023 | $-1.58 | 16.18% |
| 2022 | $-1.36 | 29.52% |
| 2021 | $-1.05 | 100.08% |
| 2020 | $-0.52 | 40.62% |
| 2019 | $-0.37 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,840.00% |
US
|
|
| $-7.07 | 685.56% |
US
|
|
| $-5.29 | 487.78% |
AU
|
|
| $12.88 | -1,531.12% |
BE
|
|
| $21.56 | -2,495.56% |
NL
|
Questions about Recursion Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Recursion Pharmaceuticals, Inc.'s earnings per share (EPS)?
Recursion Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-0.90, as of Sep 2026.
What was Recursion Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Recursion Pharmaceuticals, Inc.'s earnings per share (EPS) was $-1.44, compared with $-1.69 in 2024.
How has Recursion Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Recursion Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.52) and lowest in 2024 ($-1.69).
How does Recursion Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Recursion Pharmaceuticals, Inc.'s earnings per share (EPS) ($-0.90) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.